Natural history, recurrence, and progression in superficial bladder cancer
- PMID: 17619739
- PMCID: PMC5917231
- DOI: 10.1100/tsw.2006.404
Natural history, recurrence, and progression in superficial bladder cancer
Abstract
Superficial bladder cancer encompasses patients with stage Ta T1 tumors and patients with carcinoma in situ (CIS). The natural history or treatment-related prognosis of these patients varies considerably from one patient to the next based on the patient's clinical and the tumor's pathological characteristics. Based on a review of the literature, the most important prognostic factors for recurrence are the prior recurrence rate, number of tumors, and tumor size; whereas for progression, the most important prognostic factors are the T category, grade, and presence of CIS. Treatment with intravesical bacillus Calmette-Guerin reduces both the risk of recurrence and the risk of progression, and is the treatment of choice in high-risk papillary tumors and in patients with CIS. Assessment of a patient's prognostic factors and his or her risk of recurrence and progression is a prerequisite for determining the most appropriate treatment and frequency of follow-up for a given patient.
Similar articles
-
Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.Eur Urol. 2005 Jul;48(1):53-9; discussion 59. doi: 10.1016/j.eururo.2005.03.021. Epub 2005 Apr 7. Eur Urol. 2005. PMID: 15967252
-
Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.Semin Urol Oncol. 1996 Feb;14(1 Suppl 1):10-6. Semin Urol Oncol. 1996. PMID: 8727805 Clinical Trial.
-
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.Eur Urol. 2015 Jan;67(1):74-82. doi: 10.1016/j.eururo.2014.06.040. Epub 2014 Jul 16. Eur Urol. 2015. PMID: 25043942
-
The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.J Urol. 2001 Mar;165(3):745-56. J Urol. 2001. PMID: 11176460 Review.
-
Guidelines on diagnosis and treatment of superficial bladder cancer.Minerva Urol Nefrol. 2004 Mar;56(1):65-72. Minerva Urol Nefrol. 2004. PMID: 15195031 Review.
Cited by
-
New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer.Korean J Urol. 2015 Aug;56(8):553-64. doi: 10.4111/kju.2015.56.8.553. Epub 2015 Jul 31. Korean J Urol. 2015. PMID: 26279824 Free PMC article. Review.
-
Short stature, digit anomalies and dysmorphic facial features are associated with the duplication of miR-17 ~ 92 cluster.Mol Cytogenet. 2014 Apr 16;7:27. doi: 10.1186/1755-8166-7-27. eCollection 2014. Mol Cytogenet. 2014. PMID: 24739087 Free PMC article.
-
Small extracellular vesicles in cancer.Bioact Mater. 2021 Apr 7;6(11):3705-3743. doi: 10.1016/j.bioactmat.2021.03.015. eCollection 2021 Nov. Bioact Mater. 2021. PMID: 33898874 Free PMC article. Review.
-
Effect of continuous saline bladder irrigation with concomitant single instillation of chemotherapy after transurethral resection on intravesical recurrence in patients with non-muscle-invasive bladder cancer.Mol Clin Oncol. 2020 Sep;13(3):6. doi: 10.3892/mco.2020.2079. Epub 2020 Jun 25. Mol Clin Oncol. 2020. PMID: 32754320 Free PMC article.
-
The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer.Int J Mol Sci. 2023 Dec 23;25(1):269. doi: 10.3390/ijms25010269. Int J Mol Sci. 2023. PMID: 38203437 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical